Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

Core Insights - Avadel Pharmaceuticals has appointed Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement, bringing over 20 years of healthcare operations experience [1][2] - The company emphasizes the importance of patient support and experience with its product LUMRYZ, which is the first and only once-at-bedtime oxybate approved for narcolepsy treatment [2][3] - Mr. Melkonian's previous experience includes leadership roles at Takeda Pharmaceuticals and CVS Health, which will aid in accelerating LUMRYZ's adoption [2][3] Company Overview - Avadel Pharmaceuticals is focused on transforming medicines to improve patient lives, with a commitment to innovative solutions in medication development [3] - LUMRYZ is specifically approved for treating cataplexy or excessive daytime sleepiness (EDS) in patients aged 7 years and older with narcolepsy [3]